The most reported treatment-related adverse events (TRAEs) in the ITT population were neutropenia, leukopenia, alopecia, elevated alanine aminotransaminase (ALT) and elevated aspartate aminotransferase (AST) (Table 5). The gene discussed is GPT; the disease is Decreased total leukocyte count.